Stem cell therapy for type 1 diabetes mellitus

doi:10.3969/j.issn.2095-4344.2015.19.024

Abstract

Abstract:

BACKGROUND: Type 1 diabetes mellitus is an autoimmune attack characterized by the selective destruction of pancreatic cells. Patients need to rely on external insulin to survive, and there is a lack of specific treatment.
OBJECTIVE: To review the source of all kinds of stem cells, differentiation capacity, self-exclusion and existing problems, and to provide the basis for regeneration treatment of type 1 diabetes mellitus.
METHODS: In order to search relevant article about stem cell therapies for type 1 diabetes mellitus from PubMed database (from 2003 to 2015), a computer-based search was performed using the key words of “type 1 diabetes mellitus, stem cell, stem cell therapy, regeneration treatment, stem-cell differentiation, stem-cell transplantation, immune suppression, insulin secreting cells, islet β-cells, therapeutic effect” in English. Finally, 42 articles were chosen for further analysis.
RESULTS AND CONCLUSION: Stem cell therapy for type 1 diabetes mellitus has attracted quite a lot of attentions. Restoration of damaged β-cells by exogenous stem cell transplantation is the currently ideal therapeutic options, that is, stem cells cultured under suitable conditions can be induced into islet β-cells that have endocrine function. Through all kinds of research, this paper expounds the source of stem cells, directional differentiation, purification, immune suppression characteristics and existing problems, and it also has a discussion for the occurrence and development of type 1 diabetes mellitus so as to select the best scheme of stem cells, which helps to cure the disease.

Key words: Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Stem Cell Transplantation

CLC Number:

R318

Bai Yu. Stem cell therapy for type 1 diabetes mellitus [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(19): 3096-3101.

Figures/Tables 1

References

[1] El-Ziny MA, Salem NA, El-Hawary AK, et al. Epidemiology of childhood type 1 diabetes mellitus in Nile Delta, northern Egypt - a retrospective study. J Clin Res Pediatr Endocrinol. 2014;6(1):9-15.

[2] van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91(1):79-118.

[3] Zóka A, Somogyi A, Firneisz G. Type 1 diabetes mellitus: most recent advances in its pathogenesis and treatment. Orv Hetil. 2012;153(27):1047-1056.

[4] Patelarou E, Girvalaki C, Brokalaki H, et al. Current evidence on the associations of breastfeeding, infant formula, and cow's milk introduction with type 1 diabetes mellitus: a systematic review. Nutr Rev. 2012;70(9):509-519.

[5] Morran MP, Vonberg A, Khadra A, et al. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med. 2015;42:42-60.

[6] Martinez PJ, Mathews C, Actor JK, et al. Impaired CD4+ and T-helper 17 cell memory response to Streptococcus pneumoniae is associated with elevated glucose and percent glycated hemoglobin A1c in Mexican Americans with type 2 diabetes mellitus. Transl Res. 2014;163(1):53-63.

[7] Michalek J, Vrabelova Z, Hrotekova Z, et al. Immune regulatory T cells in siblings of children suffering from type 1 diabetes mellitus. Scand J Immunol. 2006;64(5):531-535.

[8] Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. Int Immunopharmacol. 2014; 22(1): 182-191.

[9] Li M, Song LJ, Qin XY. Advances in the cellular immunological pathogenesis of type 1 diabetes. J Cell Mol Med. 2014;18(5): 749-758.

[10] Adamson KA, Cheetham TD, Kendall-Taylor P, et al. The role of the IDDM2 locus in the susceptibility of UK APS1 subjects to type 1 diabetes mellitus. Int J Immunogenet. 2007;34(1): 17-21.

[11] Zóka A, Barna G, Somogyi A, et al. Extension of the CD4+Foxp3+CD25-/low regulatory T-cell subpopulation in type 1 diabetes mellitus. Autoimmunity. 2014:1-9.

[12] Fridell JA, Rogers J, Stratta RJ. The pancreas allograft donor: current status, controversies, and challenges for the future. Clin Transplant. 2010;24(4):433-449.

[13] Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105(3):369-377.

[14] Lin PY, Hung SH, Yang YC, et al. A synthetic peptide-acrylate surface for production of insulin-producing cells from human embryonic stem cells. Stem Cells Dev. 2014;23(4):372-379.

[15] Kahan BW, Jacobson LM, Hullett DA, et al. Pancreatic precursors and differentiated islet cell types from murine embryonic stem cells: an in vitro model to study islet differentiation. Diabetes. 2003;52(8):2016-2024.

[16] Brolén GK, Heins N, Edsbagge J, et al. Signals from the embryonic mouse pancreas induce differentiation of human embryonic stem cells into insulin-producing beta-cell-like cells. Diabetes. 2005;54(10):2867-2874.

[17] Kwon YD, Oh SK, Kim HS, et al. Cellular manipulation of human embryonic stem cells by TAT-PDX1 protein transduction. Mol Ther. 2005;12(1):28-32.

[18] Xiao X, Chen Z, Shiota C, et al. No evidence for β cell neogenesis in murine adult pancreas. J Clin Invest. 2013; 123(5):2207-2217.

[19] Calafiore R, Montanucci P, Basta G. Stem cells for pancreatic β-cell replacement in diabetes mellitus: actual perspectives. Curr Opin Organ Transplant. 2014;19(2):162-168.

[20] Szot GL, Yadav M, Lang J, et al. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell. 2015;16(2):148-157.

[21] Cavelti-Weder C, Shtessel M, Reuss JE, et al. Pancreatic duct ligation after almost complete β-cell loss: exocrine regeneration but no evidence of β-cell regeneration. Endocrinology. 2013;154(12):4493-4502.

[22] Lee KO, Gan SU, Calne RY. Stem cell therapy for diabetes. Indian J Endocrinol Metab. 2012;16(Suppl 2):S227-229.

[23] Aali E, Mirzamohammadi S, Ghaznavi H, et al. A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats. J Diabetes Metab Disord. 2014;13(1):76.

[24] Mesples A, Majeed N, Zhang Y, et al. Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: preliminary results. Med Sci Monit. 2013;19: 852-857.

[25] Li M, Ikehara S. Bone-marrow-derived mesenchymal stem cells for organ repair. Stem Cells Int. 2013;2013:132642.

[26] Malgieri A, Kantzari E, Patrizi MP, et al. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med. 2010;3(4):248-269.

[27] Trivedi HL, Vanikar AV, Thakker U, et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc. 2008;40(4):1135-1139.

[28] Pan XH, Song QQ, Dai JJ, et al. Transplantation of bone marrow mesenchymal stem cells for the treatment of type 2 diabetes in a macaque model. Cells Tissues Organs. 2013; 198(6):414-427.

[29] Ianus A, Holz GG, Theise ND, et al. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J Clin Invest. 2003; 111(6):843-850.

[30] Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297 (14):1568-1576.

[31] Karaoz E, Okcu A, Ünal ZS, et al. Adipose tissue-derived mesenchymal stromal cells efficiently differentiate into insulin-producing cells in pancreatic islet microenvironment both in vitro and in vivo. Cytotherapy. 2013;15(5):557-570.

[32] Teichert AM, Pereira S, Coles B, et al. The neural stem cell lineage reveals novel relationships among spermatogonial germ stem cells and other pluripotent stem cells. Stem Cells Dev. 2014;23(7):767-778.

[33] Morimoto H, Iwata K, Ogonuki N, et al. ROS are required for mouse spermatogonial stem cell self-renewal. Cell Stem Cell. 2013;12(6):774-786.

[34] Guo XR, Wang XL, Li MC, et al. PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro. Clin Exp Med. 2014 Oct 28. [Epub ahead of print]

[35] Godfrey KJ, Mathew B, Bulman JC, et al. Stem cell-based treatments for Type 1 diabetes mellitus: bone marrow, embryonic, hepatic, pancreatic and induced pluripotent stem cells. Diabet Med. 2012;29(1):14-23.

[36] Li SW, Koya V, Li Y, et al. Pancreatic duodenal homeobox 1 protein is a novel beta-cell-specific autoantigen for type I diabetes. Lab Invest. 2010;90(1):31-39.

[37] Ende N, Chen R, Reddi AS. Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochem Biophys Res Commun. 2004;325(3):665-669.

[38] Haller MJ, Viener HL, Wasserfall C, et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008;36(6):710-715.

[39] BarNur O, Russ HA, Efrat S, et al. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011;9(1):17-23.

[40] Kuise T, Noguchi H, Tazawa H, et al. Establishment of a pancreatic stem cell line from fibroblast-derived induced pluripotent stem cells. Biomed Eng Online. 2014;13:64.

[41] Zavazava N. Progress toward establishing embryonic stem or induced pluripotent stem cell-based clinical translation. Curr Opin Organ Transplant. 2014;19(6):598-602.

[42] Golestaneh N, Kokkinaki M, Pant D, et al. Pluripotent stem cells derived from adult human testes. Stem Cells Dev. 2009; 18(8):1115-1126.